Replimune’s $100.5 Million Initial Public Offering

Cravath represented the underwriters, J.P. Morgan Securities, Leerink Partners and BMO Capital Markets, in connection with the $100.5 million initial public offering of the common stock of Replimune Group, Inc., a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform.

The shares were listed on the Nasdaq Global Select Market. The transaction closed on July 24, 2018.

The Cravath team included partners Johnny G. Skumpija (Picture) and William V. Fogg and associates William F. Roegge and Ana Drmanovic on securities matters; partner David J. Kappos and practice area attorney Anthony N. Magistrale on intellectual property matters; associate Kiran Sheffrin on tax matters; and associate Philip F. Schreiber on executive compensation and benefits matters. Summer associate Benjamin J. Barocas also worked on securities matters.

Involved fees earner: Johnny Skumpija – Cravath Swaine & Moore; William V. Fogg – Cravath Swaine & Moore; William Roegge – Cravath Swaine & Moore; Ana Drmanovic – Cravath Swaine & Moore; Anthony N. Magistrale – Cravath Swaine & Moore; Kiran Sheffrin – Cravath Swaine & Moore; Philip Schreiber – Cravath Swaine & Moore;

Law Firms: Cravath Swaine & Moore;

Clients: JP Morgan Securities; Leerink Partners; BMO Capital Markets;

Author: Ambrogio Visconti